Cargando…

Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab

BACKGROUND: The ECOG-ACRIN Cancer Research Group evaluated rituximab treatment schedules for patients with newly-diagnosed low-tumor-burden follicular-lymphoma (FL). All patients received 4-weekly rituximab treatments as induction therapy. Clinically-responding patients were randomized to receive ri...

Descripción completa

Detalles Bibliográficos
Autores principales: Erbe, Amy K., Wang, Wei, Carmichael, Lakeesha, Hoefges, Anna, Grzywacz, Bartosz, Reville, Patrick K., Ranheim, Erik A., Hank, Jacquelyn A., Kim, KyungMann, Seo, Songwon, Mendonca, Eneida A., Song, Yiqiang, Kenkre, Vaishalee P., Hong, Fangxin, Gascoyne, Randy D., Paietta, Elisabeth, Horning, Sandra J., Miller, Jeffrey S., Kahl, Brad, Sondel, Paul M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419437/
https://www.ncbi.nlm.nih.gov/pubmed/30871628
http://dx.doi.org/10.1186/s40425-019-0538-8

Ejemplares similares